CIK 0001211583 · Non-accelerated filer<br>Smaller reporting company
FENNEC PHARMACEUTICALS INC.
Sign in to watch- Ticker
- FENC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- British Columbia, Canada
- Entity type
- operating
- Phone
- (919) 636-4530
- Business address
- PO BOX 13628, 68 TW ALEXANDER DRIVE, RESEARCH TRIANGLE PARK, NC, 27709
- Former names
- ADHEREX TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,310,718
- in 4 filings, $1.2M under 10b5-1 plans
Net −$1,310,718. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-03 | Raykov Rosty CHIEF EXECUTIVE OFFICER | Option exercise | +74,793 | $1.59 | $119K | 307,631 |
| 2023-11-03 | Raykov Rosty CHIEF EXECUTIVE OFFICER | Option exercise · Option Contract | −74,793 | $1.59 | $119K | 1,596,040 |
| 2023-08-18 | RALLIS CHRIS A Director | Sale 10b5-1 | −673 | $7.85 | $5K | 43,303 |
| 2023-08-07 | Haigh Adrian CHIEF OPERATING OFFICER | Grant or award · Stock Option | +200,000 | 493,579 | ||
| 2023-07-24 | RALLIS CHRIS A Director | Option exercise 10b5-1 | +16,666 | $0.72 | $12K | 50,772 |
| 2023-07-24 | RALLIS CHRIS A Director | Sale 10b5-1 | −6,796 | $8.17 | $56K | 43,976 |
| 2023-07-24 | RALLIS CHRIS A Director | Option exercise · Common Shares 10b5-1 | −16,666 | $0.72 | $12K | 187,312 |
| 2023-07-06 | RALLIS CHRIS A Director | Sale 10b5-1 | −2,207 | $8.47 | $19K | 28,826 |
| 2023-07-06 | RALLIS CHRIS A Director | Option exercise 10b5-1 | +5,280 | $0.96 | $5K | 34,106 |
| 2023-07-06 | RALLIS CHRIS A Director | Option exercise · Common Shares 10b5-1 | −5,208 | $0.96 | $5K | 203,978 |
| 2023-06-30 | Andrade Robert CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −7,500 | $8.82 | $66K | 124,721 |
| 2023-06-30 | Andrade Robert CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +25,000 | $2.45 | $61K | 149,721 |
| 2023-06-30 | Andrade Robert CHIEF FINANCIAL OFFICER | Option exercise · Common Shares 10b5-1 | −25,000 | $2.45 | $61K | 605,000 |
| 2023-06-29 | Andrade Robert CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −7,500 | $8.97 | $67K | 132,221 |
| 2023-06-28 | Andrade Robert CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −10,000 | $8.99 | $90K | 139,721 |
| 2023-06-12 | Islam Khalid Director | Grant or award · Stock Option | +25,000 | 388,825 | ||
| 2023-06-12 | Cook Jodi A Director | Grant or award · Stock Options | +20,000 | 100,000 | ||
| 2023-06-12 | RALLIS CHRIS A Director | Grant or award · Stock Option | +20,000 | 209,186 | ||
| 2023-06-12 | Brughera Marco Maria Director | Grant or award · Stock Option | +20,000 | 175,545 | ||
| 2023-06-12 | Haigh Adrian Director | Grant or award · Stock Option | +20,000 | 293.58 |
Page 17 of 17 · 340 trades